J-Pharma’s LAT1 Inhibitor JPH034 Initiates Phase 1 Clinical Trial in the United States – Axcelead DDP Supported Multiple IND-Enabling Studies –
J-Pharma Co., Ltd. (“J-Pharma”) has announced that dosing …
Move your hits to candidates faster with Axcelead
Axcelead delivers quality with speed. We maintain an 84% client …
Irbesartan but not Roflumilast Ameliorates Renal Injury in a Col4a5 R471* Mutant Mouse Model of Alport Syndrome and CKD
The World Congress of Nephrology 2026
Inducible Exon Skipping After Disease Onset as a Therapeutic Strategy for CKD：Evaluation in a Patient-Derived Mouse Model of Alport Syndrome
The World Congress of Nephrology 2026
Co-authored Paper by Researcher Matsumoto and Researcher Miura of the Translational Research Business Unit Published in Gut Pathogens
Cross-organ multi-omics profiling of microbiome and metabolome along …
Researcher Yamamoto from Pharmacology Business Unit to Present a Poster at the World Congress of Nephrology 2026
Researcher Yamamoto from Pharmacology Business Unit, will deliver …
Researcher Hashikami from Pharmacology Business Unit to Present a Poster at the World Congress of Nephrology 2026
Researcher Hashikami from Pharmacology Business Unit , will …
Proteros and Axcelead DDP Enter Strategic Collaboration to Enhance Discovery Capabilities
Proteros and Axcelead DDP Enter Strategic Collaboration to …